Bibliography
- PENG KW: Strategies for targeting therapeutic gene delivery. Mol. Med. Today (1999) 5:448–453.
- •General overview of the approaches to transfer genes efficiently to specific cell types.
- DASS CR, BURTON MA: Microsphere-mediated targeted gene therapy of solid tumors. Drug Delivery (1999) 6:243–252.
- LIU MJ, FRECHET JMJ: Designing dendrimers for drug delivery. Pharm. ScL Technol. Today (1999) 2:393–401.
- PENG KW, RUSSELL SJ: Viral vector targeting. Curr. Opin. Biotechnol (1999) 10:454–457.
- KABANOV AV: Taking polycation gene delivery systems from in vitro to in vivo. Pharm. ScL Technol Today (1999) 2:365–372.
- GARNETT MC: Gene-delivery systems using cationicpolymers. Grit. Rev. Ther. Drug Carrier Syst. (1999) 16:147–207.
- TEMPLETON NS, LASIC DD: New directions in liposomegene delivery. Mol. Biotechnol. (1999) 11:175–180
- MUDERHWA JM, MATYAS GR, SPITLER LE, ALVING CR:Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. J. Pharm. ScL (1999) 88(12):1332–1339.
- •This describes the potential use of liposomes containing encapsulated antigen in the formulation of oil-in-water vaccines.
- SINGH M, OHAGAN D: Advances in vaccine adjuvants. Nature Biotechnol. (1999) 17(10:1075–1081.
- ••This reviews the latest developments in novel vaccineadjuvants and raises awareness of the potential develop-ment of more potent adjuvants, which may allow the use of vaccines as therapeutic rather than prophylactic agents.
- NASI ML, LIEBERMAN P, BUSAM KJ et al.: Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Mol Ther. (1999) 5 (3) :139–144.
- •Identifies the potential use of intradermal injection of granulocyte-macrophage colony-stimulating factor for the pretreatment of skin prior to vaccination.
- BELPERRON AA, FELTQUATE D, FOX BA, HORII T, BZIK DJ: Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum. Infect. Immun. (1999) 67(105163–5169.
- •Provides evidence for the use of DNA vaccination as a viable alternative or in combination with protein based vaccines to maximise the efficacy of human malaria vaccine.
- HAYASHI A, NAKANISHI T, KUNISAWA J et al.: A novel vaccine delivery system using immunopotentiating fusogenic liposomes. Biochem. Biophys. Res. Commun. (1999) 261(3):824–828.
- ••An interesting approach to enhancing immunologicalresponse to vaccination.
- JENKINS PG: Mucosal vaccine delivery. Exp. Opin. Ther. Patents (1999) 9(3):255–262.
- ••A useful review of the recent patent literature on mucosalvaccine delivery.
- DODANE V, VILIVALAM VD: Pharmaceutical applications of chitosan. Pharma. ScL Technol. Today (1998) 1(6)246–253.
- •A general review of the pharmaceutical applications of chitosans.
- ILLUM L: Chitosan and its use as a pharmaceutical excipient. Pharma. Res. (1998) 15:1326–1331.
- ••An in-depth review of the pharmaceutical applications ofchitosan.
- JONES MC, LEROUX JC: Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharma. Biopharma. (1999) 48:101–111.
- LEGRAND P, BARRATT G, MOSQUEIRA V, FESSI H, DEVISSAGUET JP: Polymeric nanocapsules as drug delivery systems - a review. Stp Pharma Sciences (1999) 9:411–418.